Japan’s First Committee On Drugs Approves Three New Drugs Including J&J Schizophrenia Drug
This article was originally published in PharmAsia News
Executive Summary
Japan’s PAFSC First Committee on Drugs approved three new drugs, including intramuscular schizophrenia drug Xeplion (paliperidone palmitate) from Janssen, already approved in 66 countries.